USA flag logo/image

An Official Website of the United States Government

Wearable muscle fiber excitation system for preventing blood clot

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43MH101892
Solicitation Year:
2013
Solicitation Topic Code:
NIMH
Solicitation Number:
PA12-088
Small Business Information
GRADIENT BIOMODELING, LLC
8040 JUNIPER DRIIVE PARK CITY, UT 84098-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Wearable muscle fiber excitation system for preventing blood clot
Agency: HHS
Contract: 1R43MH101892-01
Award Amount: $350,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Schizophrenia is a complex psychiatric disorder with a heterogeneous clinical phenotype. It is probably one of the most costly psychiatric illnesses, yet the development of novel and safe antipsychotics lags behind. Amplifying the actions of endocannabinoids by inhibiting their enzymatic degradation has emerged as an alternative strategy to exploit the endocannabinoid system for possible clinical benefit. Here, we propose to apply a quantum-similarity approach to discover novel modulators (inhibitors) of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), aiming to elevate endocannabinoid tone to relieve the negative symptoms of schizophrenia. Instead of blindly screening millions of compounds for novelmodulators of the target of interest, our focused testing of 10-20 commercially available compounds per target (pathway, protein etc.) with predicted (inhibitory) activity by the modeling effort, allows us to quickly explore novel chemical spaces for therapeutic applications, specifically and accurately targeting elusive, hard to modulate protein- protein interactions previously considered unapproachable by current discovery methods. The modeling, virtual search, identification and rank ordering of novel classes of FAAH and MAGL inhibitors, as well as the de novo design of novel antipsychotics will be done by Gradient Biomodeling. The in vitro and in vivo experimental evaluation of the compounds will be done in the laboratory of Dr. Andrea Giuffrida, at theUniversity of Texas Health Science Center at San Antonio. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Schizophrenia is a complex psychiatric disorder with a heterogeneous clinical phenotype. It is one of the most costly psychiatric illnesses, not only in terms of direct cost but also as a result of its long-term impact and loss of productivity, requirig intensive medical psychiatric care as well as the indefinite need for social and economic support. Here, we propose to apply a quantum-similarity approach to discover novel modulators (inhibitors) of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), aiming to elevate endocannabinoid tone to relieve the negative symptoms of schizophrenia.

Principal Investigator:

Martin N. Martinov
202-640-9576
martinov.mn@gradientbiomodeling.com

Business Contact:

Nick Kaludov
202-640-9576
kaludov.n@gradientbiomodeling.com
Small Business Information at Submission:

GRADIENT BIOMODELING, LLC
8040 JUNIPER DRIIVE PARK CITY, UT 84098-

EIN/Tax ID: 126463430
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No